Senior Advisor Appointment
June 28 2007 - 3:01AM
UK Regulatory
RNS Number:1588Z
Libertas Capital Group PLC
28 June 2007
For immediate release 28 June 2007
LIBERTAS CAPITAL GROUP PLC
("Libertas Capital" or "the Company")
APPOINTMENT OF SENIOR ADVISOR TO LIBERTAS CAPITAL
Libertas Capital Group plc (AIM: LBR), the financial services firm, is pleased
to announce that Professor Trevor M Jones, Ph.D has joined the Company as a
Senior Advisor to Libertas Capital.
Prof. Jones was appointed to the Board of Allergan in 2004 and elected in 2005.
From 1994 to 2004, he was Director General of the Association of the British
Pharmaceutical Industry (ABPI). From 1987 to 1994, he was a main Board Director
at Wellcome plc. Prof. Jones received his bachelor of pharmacy degree and Ph.D.
from the University of London and is currently Vice Chairman of Council at
King's College, London.
He has also gained an honorary doctorate from the University of Athens as well
as honorary doctorates in science from the Universities of Strathclyde,
Nottingham, Bath and Bradford in the United Kingdom. Furthermore, he was
recognised in the Queen's Honours List and holds the title of Commander of the
British Empire.
Prof. Jones is also a fellow of the Royal Society of Chemistry, a fellow of The
Royal Pharmaceutical Society and an honorary fellow of the Royal College of
Physicians and of its Faculty of Pharmaceutical Medicine and an honorary fellow
of the British Pharmacological Society.
He is Chairman of the Board of ReNeuron Group plc and of B.A.C. BV and a board
member of Merlin Biosciences' Funds I and II and NextPharma Technologies
Holdings Ltd. He is also a founder and board member of the Geneva-based
public-private partnership, Medicines for Malaria Venture and the UK Stem Cell
Foundation.
Commenting on this appointment, Jakob Kinde, Executive Chairman of Libertas
Capital, said: "We are confident that Prof. Jones' knowledge and experience will
enable him to make an important contribution to the business of Libertas
Capital. The wealth of his experience in the pharmaceutical and healthcare
sector will be of particular importance to us as this is one of the Group's key
strategic sectors. We extend a warm welcome to him in this new role of Senior
Advisor."
For further information please contact:
Libertas Capital Group plc +44 (0)20 7569 9650
Jakob Kinde, Executive Chairman
Henry Okereke, Chief Executive
Grant Thornton +44 (0)20 7383 5100
Fiona Owen/Fiona Kindness
Buchanan Communications +44 (0)20 7466 5000
Charles Ryland /Mary-Jane Johnson
Notes to Editors
About Libertas Capital Group plc
Libertas Capital is a financial services firm offering its clients a full range
of dedicated independent Corporate Finance Advisory, Research and Distribution
services in Europe, North America, Asia and the Middle East.
Corporate Finance services include advice on M&A, public and private fund
raising, private equity encompassing development capital, MBOs and MBIs,
valuation and exit strategy. In the Securities business Libertas Capital offers
research to corporate and institutional clients, via Equity Growth Research and
Libertas Capital Research, over a global distribution network. Securities also
offers a dedicated sales distribution team catering for institutions and high
net worth individuals.
Libertas Capital is focused on the small to mid cap market in Europe, North
America, Asia and the Middle East where the Group has gained widespread
experience and developed strong relationships. Libertas Capital concentrates
primarily on growth companies across a number of industry sectors with a
particular focus on Renewable Energy, Energy (oil and gas, oil services and
natural resources), Technology (software, services and telecoms) and Healthcare.
This information is provided by RNS
The company news service from the London Stock Exchange
END
MSCBLGDLGUDGGRR
Libertas Capital (LSE:LBR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Libertas Capital (LSE:LBR)
Historical Stock Chart
From Jul 2023 to Jul 2024
